Brain Cancer Stem Cells: A Level Playing Field  by Pollard, Steven et al.
Cell Stem Cell
LetterBrain Cancer Stem Cells: A Level Playing Field
Steven Pollard,1 Ian D. Clarke,2 Austin Smith,1 and Peter Dirks,2,* (on behalf of all authors)
1Wellcome Trust Centre for Stem Cell Research and Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge,
CB2 1QR, UK
2Arthur and Sonia Labatt Brain Tumor Research Center, Program in Developmental and Stem Cell Biology, The Hospital for Sick Children,
University of Toronto, Toronto, 555 University Avenue, Toronto, ON M5G 1X8, Canada
*Correspondence: peter.dirks@sickkids.ca
DOI 10.1016/j.stem.2009.10.016The well-established neurosphere culture
method has undoubtedly been valuable
in the development of the field of neural
stem cell research. However, it is incum-
bent on scientific investigators to consider
the possibility that two complementary
approaches can be more or less suitable
for different types of experiments. We
have previously reported long-term prop-
agation of neural stem cells as stable
adherent cell lines (Conti et al., 2005; Sun
et al., 2008). Our recent study published
in Cell Stem Cell extended these findings
to the human brain cancer glioblastoma
(Pollard et al., 2009). The objective of our
study was not to criticize the neurosphere
method, but to present an alternative
which offers certain advantages and
opens up new opportunities.
Maintaining cells in monolayer culture
has several significant features compared
with suspension cultureof cell aggregates:
(1) cells are exposed uniformly to growth
factors, nutrients, and other additives; (2)
differentiation and apoptosis are sup-
pressed; (3) colonies remaindiscrete, facil-
itating clonal assay and propagation; (4)
routine culture is standardized and experi-
mental manipulations such as transfec-
tion, immunostaining, and generation of
single-cell suspensions for flow cytometry
are facile; (5) individual cells canbe imaged
continuously during self-renewal or differ-
entiation,allowingcaptureof featuressuch
as cell migration, morphometry, and line-
age. For all of the above reasons adherent
cultures are ideally suited for high-content
genetic and chemical screening.
In their Letter, Reynolds and Vescovi.
(2009) raise technical criticisms of the
experiments we’ve conducted that com-
pare the adherent protocol with neuro-
sphere cultures. We address these issues
in order:
(1) Differentiation in spheres (in our
study) is due to overgrowth.
It is well established that neurospheres
are heterogeneous and contain differenti-468 Cell Stem Cell 5, November 6, 2009 ª2ated cells. A review article coauthored by
A. Vescovi (Galli et al., 2003) contains the
following statement: ‘‘It should be noted
thatnotall theNSCprogeny found inaneu-
rosphere are stem cells. Indeed, only 10%
to 50% of these progeny retain stem cell
features, whereas the remainder are cells
that undergospontaneousdifferentiation.’’
In our side-by-side comparison of sus-
pension culture with adherent culture
(Figure 2 and Figure S1B), we plated cells
at the same density and grew them for an
identical period of 7 days. We observed
larger numbers of differentiation markers
within the spheres, even those of small
size (<100 mM), as analyzed both by con-
focal microscopy and quantitatively by
intracellular flow cytometry.
It seems to us that Figure S1Bmay have
been misinterpreted by Reynolds and
Vescovi. The notion that absolute levels
of nestin define a stem cell is unfounded.
There is general agreement, however,
that a cell lacking nestin is unlikely to be
a stem cell. Our data show unequivocally
that in adherent cultures, the majority of
cells are nestin positive, while in sphere
culture, the same cell line generates a
large population of nestin-negative cells.
Reynolds and Vescovi suggest that the
problem of differentiation in spheres may
be overcome by passaging at an unde-
fined ‘‘early enough stage.’’ While this
may be possible, it is hardly practical
for large-scale expansion and screening.
Furthermore, neurospheres fuse with
one another even at low cell densities
(10–20 cells/ml), resulting in formation of
larger aggregates (Coles-Takabe et al.,
2008; Singec et al., 2006). Indeed, to over-
come this problem, Reynolds and others
have resorted to culturing spheres in
semisolid collagen matrix or encapsu-
lated in agarose (Coles-Takabe et al.,
2008; Louis et al., 2008), methods that
are not readily scaleable.
(2) Adherent cell lines are not potently
tumorigenic.009 Elsevier Inc.This point may also arise from a misun-
derstanding of the data in the manuscript.
The efficiency of engraftment of freshly
isolatedprimary tumor cells (suchas those
wepreviously isolatedwithCD133) should
not be directly compared to that of estab-
lished cell lines. We consider that anal-
ysis of primary tumor samples remains
the gold-standard assay for cancer stem
cells. However, derivation of permanent
cell lines that retain cancer-initiating po-
tential is invaluable for a range of experi-
mental investigations. Our observation of
engraftment and tumor initiation at low
cell numbers (100) for adherent lines will
enable limiting-dilution assays to test
chemical and genetic manipulations. In-
terestingly, 200,000–300,000 sphere cells
were injectedby theVescovi group to form
tumors (Galli et al., 2004).
(3) Apoptosis is not quantitated for the
different culture conditions.
TUNEL staining and quantitative as-
sessment of Annexin by flow cytometry
clearly demonstrate apoptosis in spheres.
Adherent GNS cells do not exhibit sig-
nificant levels of apoptosis by these
measures. Furthermore, time-lapse moni-
toring of the cultures shows no evidence
that appreciable numbers of cells die
and detach (supplemental movies).
(4) Lack of differentiation markers does
not equate to pure stem cells.
We agree that lack of differentiation
markers does not define a stem cell. How-
ever, absence of differentiated features is
an expected requirement of a stem cell.
Self-renewal is demonstrated by repeated
passaging, with retention of differentiation
capacity consistent with the primary
tumor. There is no practical assay that
can demonstrate each cell within a culture
is a stem cell, although we accept that
additional clonal data would be valuable.
The thought experiment that if adherent
cultures are more highly enriched in
stem cells than spheres they should
expand much faster is intriguing. A high
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cell (Reynolds and Rietze, 2005). In
many systems, stem cells are thought to
proliferate slowly or even be dormant
for periods, with proliferative potential
residing primarily in progenitor or transit-
amplifying cells.
(5) Efficiency of generating glioma stem
cell cultures.
Reynolds and Vescovi claim to have
grown 150 GBM cell cultures with near
100% success. We accept that different
labs can be more or less successful with
any given technique. However, we also
note that the authors previously reported
that ‘‘half of the cultures established
from 12 glioblastoma multiforme samples
comprised multipotent precursors, which
established long-term expanding cul-
tures’’ (Galli et al., 2004). A similar
success rate of around 50% is reported
by others (Gu¨nther et al., 2007). Therefore,
a 100% success rate in deriving primary
tumor stem cell lines is by no means
a given.
In this matter, it is extremely important
to discriminate between primary cultures
and permanent cell lines. Any tissue con-
taining progenitors may proliferate tran-
siently in aggregation culture. We have
routinely obtained cultures from glioma
that expand as spheres for 3–5 passages,
but have been frustrated by the high
proportion that fail to prosper beyond 10
passages. We look forward to a detailed
description of how Reynolds and Vescovi
have overcome this problem. We also
hope they will make their cells available
to the community. We have deposited 5
adherent glioblastoma stem cell lines in
a cell repository (BioRep, Milan), andthey are available to any academic inves-
tigator under the standard terms of the
Uniform Biological Materials Transfer
Agreement.
Reynolds and Vescovi draw attention to
our observation that in some cases, tumor
cells aggregated in suspension for a short
period before adherent culture. They
suggest that this entails formation of
entities they describe as ‘‘actual neuro-
spheres.’’ We cannot discriminate a cell
aggregate from an ‘‘actual neurosphere.’’
However, contrary to the assertion by
Reynolds and Vescovi, we did not subcul-
ture cells in suspension but plated the
dissociated aggregates directly on lami-
nin.
We have experienced 9 years of frus-
tration in attempts to obtain consistent
long-term expansion of sphere cultures
derived from glioblastomas. Problematic
aspects of neurosphere culture are widely
acknowledged and include heterogeneity,
variable presence of stem cells (Reynolds
and Rietze, 2005), collapse of cultures,
difficulty of transfection, fusion between
spheres leading to lack of clonality (Singec
et al., 2006), and in addition, various arti-
factual findings (Bjornson et al., 1999).
We note that while Reynolds and Vescovi
criticize minor points in our study, they
do not suggest any potential advantage
of spheres. We encourage researchers
working on human brain cancer to try the
two approaches side by side.
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